Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.46 |
| ▸ | PDE2A | O00408 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | APLNR | P35414 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5407528 | 0.92 | AR (0.49) | MEN1KMT2APDE3BPDE3AP2RY12 | |
| SCHEMBL5412668 | 0.92 | MEN1 (0.54) | MEN1KMT2APDE3BPDE3APDE2A | |
| SCHEMBL5410432 | 0.89 | MAPT (0.50) | MEN1KMT2APDE3BPDE3AP2RY12 | |
| SCHEMBL6597060 | 0.86 | MEN1 (0.39) | MEN1KMT2APDE3BPDE3AP2RY12 | |
| SCHEMBL5414904 | 0.84 | AR (0.50) | MEN1KMT2APDE3BPDE3APDE2A | |
| SCHEMBL5409644 | 0.84 | MAPT (0.47) | PDE3BPDE3AP2RY12PDE2AAR | |
| SCHEMBL5418895 | 0.83 | PDE3B (0.52) | PDE3BPDE3AP2RY12PDE2AALDH1A1 | |
| SCHEMBL5407925 | 0.83 | PDE3B (0.51) | PDE3BPDE3AP2RY12PDE2APPARG | |
| SCHEMBL5409690 | 0.83 | PDE3B (0.51) | PDE3BPDE3AP2RY12PDE2APPARG | |
| SCHEMBL5412749 | 0.83 | PDE3B (0.53) | PDE3BPDE3AP2RY12PDE2APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404656-B9 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AG (DE) | 2005-10-19 | — | — | EP | claimed |
| EP-1404656-B1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AG (DE) | 2005-05-18 | — | — | EP | claimed |
| EP-1404656-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-07 | — | — | EP | claimed |
| US-20030125550-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2003-07-03 | — | — | US | claimed |
| WO-2003006438-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-23 | — | — | WO | claimed |
| US-7196202-B2 | 1-aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2007-03-27 | — | — | US | disclosed |
| EP-1404656-B9 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AG (DE) | 2005-10-19 | — | — | EP | disclosed |
| US-20050143439-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-30 | — | — | US | disclosed |
| US-6903126-B2 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2005-06-07 | — | — | US | disclosed |
| EP-1404656-B1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AG (DE) | 2005-05-18 | — | — | EP | disclosed |
| US-20030125550-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125550-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | MSR1, ARG2, ARG1 | MEN1 4451/4885KMT2A 2370/4885PDE3B 471/4885 |
| US-20050143439-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | MSR1, ARG2, CYBB | MEN1 4501/4885KMT2A 2159/4885PDE3B 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.